Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program

被引：0
|
作者：
Jeroen, de Filette [1 ]
Yanina, Jansen [2 ]
Max, Schreuer [2 ]
Hendrik, Everaert [3 ]
Brigitte, Velkeniers [1 ]
Bart, Neyns [2 ]
Bert, Bravenboer [1 ]
机构：
[1] VUB, Univ Ziekenhuis Brussel, Dept Endocrinol, Laarbeeklaan 101, B-1090 Brussels, Belgium
[2] VUB, Univ Ziekenhuis Brussel, Med Oncol, Laarbeeklaan 101, B-1090 Brussels, Belgium
[3] VUB, Univ Ziekenhuis Brussel, Nucl Med, Laarbeeklaan 101, B-1090 Brussels, Belgium
来源：
ACTA CLINICA BELGICA | 2016年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
    de Filette, Jeroen
    Jansen, Yanina
    Schreuer, Max
    Everaert, Hendrik
    Velkeniers, Brigitte
    Neyns, Bart
    Bravenboer, Bert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (11): : 4431 - 4439
  • [2] Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
    Baldini, Editta
    Lunghi, Alice
    Cortesi, Enrico
    Turci, Daniele
    Signorelli, Diego
    Stati, Valeria
    Melotti, Barbara
    Ricciuti, Biagio
    Frassoldati, Antonio
    Romano, Giampiero
    Ceresoli, Giovanni Luca
    Illiano, Alfonso
    Verderame, Francesco
    Fasola, Gianpiero
    Ricevuto, Enrico
    Marchetti, Paolo
    Pinto, Carmine
    Carteni, Giacomo
    Scotti, Vieri
    Tibaldi, Carmelo
    Fioretto, Luisa
    Giannarelli, Diana
    LUNG CANCER, 2020, 140 : 59 - 64
  • [3] Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab
    Mashni, Ola K.
    Baba, Dima W.
    Mahmoud, Aseel N.
    Qur'an, Tasnim O.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 577 - 581
  • [4] Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab
    Mian, Idrees
    Yang, Ming
    Zhao, Hui
    Shah, Mohsin
    Diab, Adi
    Shannon, Vickie
    Patel, Anisha
    Amaria, Rodabe Navroze
    Giordano, Sharon Hermes
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
    Gault, A.
    Anderson, A. E.
    Plummer, R.
    Stewart, C.
    Pratt, A. G.
    Rajan, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 263 - 271
  • [6] Associations between tumor response to pembrolizumab and immune-related adverse events in metastatic melanoma patients
    Geszti, F.
    Czirbesz, K.
    Kenessey, I.
    Liszkay, G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB24 - AB24
  • [7] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
    Park, Benjamin C. C.
    Narayanan, Sathya
    Gavraldis, Alexander
    Ye, Fei
    Fan, Run
    Sullivan, Ryan J. J.
    Boland, Genevieve
    Reynolds, Kerry L.
    Balko, Justin M. M.
    Carlino, Matteo S. S.
    Long, Georgina V. V.
    Zubiri, Leyre
    Menzies, Alexander M. M.
    Johnson, Douglas B. B.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [9] Immune-related adverse events: pembrolizumab ± influenza vaccine
    Reactions Weekly, 2020, 1795 (1) : 8 - 8
  • [10] Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
    Tirumani, Sree Harsha
    Ramaiya, Nikhil H.
    Keraliya, Abhishek
    Bailey, Nancy D.
    Ott, Patrick A.
    Hodi, F. Stephen
    Nishino, Mizuki
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1185 - 1192
12345